全文获取类型
收费全文 | 3971篇 |
免费 | 284篇 |
国内免费 | 26篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 196篇 |
妇产科学 | 49篇 |
基础医学 | 470篇 |
口腔科学 | 138篇 |
临床医学 | 378篇 |
内科学 | 981篇 |
皮肤病学 | 32篇 |
神经病学 | 239篇 |
特种医学 | 576篇 |
外科学 | 469篇 |
综合类 | 41篇 |
一般理论 | 1篇 |
预防医学 | 170篇 |
眼科学 | 47篇 |
药学 | 228篇 |
中国医学 | 13篇 |
肿瘤学 | 247篇 |
出版年
2022年 | 25篇 |
2021年 | 63篇 |
2020年 | 42篇 |
2019年 | 58篇 |
2018年 | 67篇 |
2017年 | 57篇 |
2016年 | 74篇 |
2015年 | 89篇 |
2014年 | 103篇 |
2013年 | 145篇 |
2012年 | 144篇 |
2011年 | 157篇 |
2010年 | 144篇 |
2009年 | 107篇 |
2008年 | 139篇 |
2007年 | 138篇 |
2006年 | 144篇 |
2005年 | 118篇 |
2004年 | 126篇 |
2003年 | 104篇 |
2002年 | 94篇 |
2001年 | 95篇 |
2000年 | 110篇 |
1999年 | 106篇 |
1998年 | 159篇 |
1997年 | 152篇 |
1996年 | 146篇 |
1995年 | 114篇 |
1994年 | 91篇 |
1993年 | 92篇 |
1992年 | 72篇 |
1991年 | 74篇 |
1990年 | 59篇 |
1989年 | 96篇 |
1988年 | 74篇 |
1987年 | 87篇 |
1986年 | 78篇 |
1985年 | 67篇 |
1984年 | 44篇 |
1983年 | 44篇 |
1982年 | 45篇 |
1981年 | 23篇 |
1980年 | 43篇 |
1979年 | 32篇 |
1978年 | 24篇 |
1977年 | 30篇 |
1976年 | 34篇 |
1975年 | 38篇 |
1972年 | 18篇 |
1970年 | 17篇 |
排序方式: 共有4281条查询结果,搜索用时 15 毫秒
91.
目的了解河北省儿童医院住院患儿EB病毒(EBV)感染的流行病学特征,为儿童EBV感染的诊断和预防提供科学依据。方法收集2017年1—12月河北省儿童医院0~14岁EBV感染住院患儿的全血样本,采用酶联免疫吸附试验(ELISA)检测其EBV衣壳抗原(VCA)IgG及IgM抗体,抗早期抗原(EA)IgG抗体和抗核抗原1(NA1)IgG抗体,以检测结果为研究样本的抗体谱。根据4种EBV抗体的检测结果分为现症感染(抗VCA-IgM抗体阳性,抗NA1-IgG抗体阴性、抗VCA-IgG抗体、抗EA-IgG抗体阳性或阴性)、亚急性感染(抗VCA-IgG抗体阳性,抗VCA-IgM抗体、抗NA1-IgG抗体、抗EA-IgG抗体阳性或阴性)、既往感染(抗NA1-IgG抗体阳性,抗VCA-IgG抗体阳性或阴性,其他抗体均为阴性)和未感染(4种抗体均阴性)。按照患儿年龄、检出月份和性别分析各组的阳性率。结果共纳入符合要求的样本4 451例,其中3 257例(73.17%)抗体谱提示EBV感染,包括现症感染380例(8.54%)、亚急性感染616例(13.84%)、既往感染2 261例(50.80%)。不同年龄组原发阳性检出率差异有统计学意义(P<0.05),其中学龄前(>3岁)组的阳性检出率最高(P<0.05);不同检出月份组阳性检出率差异有统计学意义(P<0.05),7月份阳性检出率高于其他月份(P<0.05);男性患儿与女性患儿EBV感染率差异无统计学意义(P>0.05)。380例现症感染患儿的疾病谱以血液系统疾病[传染性单核细胞增多症、急性粒细胞缺乏症、血小板减少性紫癜、EBV相关嗜血细胞综合征]为主,其中传染性单核细胞增多症为临床常见疾病;其次是呼吸系统疾病(急性支气管炎、疱疹性咽峡炎、急性扁桃体炎);其他疾病谱包括神经系统疾病及血流感染、肾病综合征、川崎病。结论河北省儿童医院住院患儿EBV阳性检出率有年龄和检出月份差异,现症感染以血液系统疾病患儿为主,医院应根据流学病学特征制定相应预防措施。 相似文献
92.
Rossi Luigi Verrico Monica Tomao Silverio Ricci Fabio Fontana Antonella Spinelli Gian Paolo Colonna Maria Vici Patrizia Tomao Federica 《Cancer chemotherapy and pharmacology》2020,85(1):105-111
Cancer Chemotherapy and Pharmacology - Many studies have indicated that the response to therapy and the prognostic impact of a pathologic complete response after neoadjuvant treatment differ among... 相似文献
93.
M. Peta E. Carretto D. Barbarini A. Zamperoni L. Carnevale L. Perversi M. Pagani M. G. Bonora R. Fontana P. Marone M. Langer 《Clinical microbiology and infection》2006,12(2):163-169
Following the identification of two clinical isolates of vancomycin-resistant enterococci (VRE) from intensive care unit (ICU) patients, a surveillance programme detected that six of eight ICU patients were colonised by VRE. Standard epidemic control measures were instituted in the ICU. During a 16-month period, 13 (2.5%) of 509 ICU patients had VRE-positive swabs upon admission, and 43 (8.7%) of 496 VRE-negative patients were colonised by VRE in the ICU. Patients who acquired VRE in the ICU had a longer ICU stay (p < 0.0001). No other statistically significant differences were demonstrated. Two patients had documented infection (infection/colonisation index, 3.6%; overall VRE infection frequency, 0.4%), but both recovered and were discharged. VRE colonisation did not increase the mortality rate. Automated ribotyping identified three clusters containing, respectively, the first 52 Enterococcus faecium isolates, two Enterococcus faecalis isolates, and two further isolates of E. faecium. Multilocus sequence typing demonstrated that two E. faecium isolates representative of the two ribotypes belonged to sequence types 78 and 18, and that these two isolates belonged to the epidemic lineage C1, which includes isolates with a wide circulation in northern Italy. The outbreak was controlled by continuous implementation of the infection control programme, and by the opening of a new unit with an improved structural design and hand-washing facilities. 相似文献
94.
Barbara Uhl Katharina T Prochazka Karoline Fechter Katrin Pansy Hildegard T Greinix Peter Neumeister Alexander JA Deutsch 《World journal of gastrointestinal oncology》2022,14(1):153-162
Approximately 8% of all non-Hodgkin lymphomas are extranodal marginal zone B cell lymphomas of mucosa-associated lymphoid tissue (MALT), also known as MALT lymphomas. These arise at a wide range of different extranodal sites, with most cases affecting the stomach, the lung, the ocular adnexa and the thyroid. The small intestine is involved in a lower percentage of cases. Lymphoma growth in the early stages is associated with long-lasting chronic inflammation provoked by bacterial infections (e.g., Helicobacter pylori or Chlamydia psittaci infections) or autoimmune conditions (e.g., Sjögren’s syndrome or Hashimoto thyroiditis). While these inflammatory processes trigger lymphoma cell proliferation and/or survival, they also shape the microenvironment. Thus, activated immune cells are actively recruited to the lymphoma, resulting in either direct lymphoma cell stimulation via surface receptor interactions and/or indirect lymphoma cell stimulation via secretion of soluble factors like cytokines. In addition, chronic inflammatory conditions cause the acquisition of genetic alterations resulting in autonomous lymphoma cell growth. Recently, novel agents targeting the microenvironment have been developed and clinically tested in MALT lymphomas as well as other lymphoid malignancies. In this review, we aim to describe the composition of the microenvironment of MALT lymphoma, the interaction of activated immune cells with lymphoma cells and novel therapeutic approaches in MALT lymphomas using immunomodulatory and/or microenvironment-targeting agents. 相似文献
95.
96.
Cháriston André Dal Belo Gildo Bernardo Leite Marcos Hikari Toyama Sergio Marangoni Alexandre Pinto Corrado Marcos Dias Fontana Andy Southan Edward G Rowan Stephen Hyslop Léa Rodrigues-Simioni 《Toxicon》2005,46(7):736-750
We have isolated a new phospholipase A2 (MiDCA1) from the venom of the coral snake Micrurus dumerilii carinicauda. This toxin, which had a molecular mass of 15,552Da, shared high sequence homology with the PLA2 toxins MICNI A and B from Micrurus nigrocinctus venom (77.7% and 73.1%, respectively). In chick biventer cervicis preparations, MiDCA1 produced concentration- and time-dependent neuromuscular blockade that reached 100% after 120 min (2.4 microM, n = 6); contractures to exogenously applied carbachol (8 microM) and KCl (13 mM) were still seen after complete blockade. In mouse phrenic-nerve diaphragm preparations, MiDCA1 (2.4 microM; n = 6) caused triphasic changes followed by partial neuromuscular blockade. Intracellular recordings of end-plate potentials (EPPs) and miniature end-plate potentials (MEPPs) from mouse diaphragm preparations showed that MiDCA1 increased the quantal content by 386+/-12% after 10 min (n = 14; p<0.05) and caused a triphasic change in the frequency of MEPPs. MiDCA1 also decreased the resting membrane potential, an effect that was prevented by tetrodotoxin and/or low extracellular calcium, but not by d-tubocurarine. The toxin increased the amplitude of mouse sciatic-nerve compound action potentials by 30+/-9% (0.6 microM; p<0.05). Potassium currents elicited in freshly dissociated dorsal root ganglia neurones were blocked by 31+/-1% (n = 4; p<0.05) in the presence of 2.4 microM MiDCA1. These results show that MiDCA1 is a new presynaptic phospholipase A2 that produces neuromuscular blockade in vertebrate nerve-muscle preparations. The triphasic effects seen in mammalian preparations and the facilitatory response were probably caused mainly by the activation of sodium channels, complemented by the blockade of nerve terminal potassium channels. The inability of d-turocurarine to prevent the depolarization by MiDCA1 indicated that cholinergic nicotinic receptors were not involved in this phenomenon. 相似文献
97.
98.
99.
100.